Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876292 | 0.92 | ALDH1A1 (0.51) | ALDH1A1DDB1CRBNMCL1KDM4E | |
| SCHEMBL28650761 | 0.90 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNMCL1KDM4E | |
| SCHEMBL31220632 | 0.78 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBNKDM4EPKM | |
| SCHEMBL6332550 | 0.77 | MCL1 (0.49) | ALDH1A1DDB1CRBNMCL1POLB | |
| SCHEMBL660307 | 0.77 | GAA (0.43) | ALDH1A1DDB1CRBNKDM4EPKM | |
| SCHEMBL27943834 | 0.76 | MCL1 (0.39) | ALDH1A1MCL1PKMPOLBMAPT | |
| SCHEMBL1018679 | 0.76 | MCL1 (0.39) | ALDH1A1MCL1PKMPOLBMAPT | |
| SCHEMBL30431491 | 0.76 | ALDH1A1 (0.49) | ALDH1A1DDB1CRBNMCL1KDM4E | |
| SCHEMBL9386437 | 0.76 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNKDM4EPKM | |
| SCHEMBL14331806 | 0.76 | CRBN (0.63) | ALDH1A1DDB1CRBNMCL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049095-B1 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION | MINTZ LIAT (US) | 2018-08-29 | — | — | EP | claimed |
| EP-3049095-A1 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION | Mintz, Liat (US) | 2016-08-03 | — | — | EP | claimed |
| CN-101443358-B | Use of ghrelin splice variants for the treatment of cachexia and/or bulimia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation | Lyat Mintz (US) | 2016-05-11 | — | — | CN | claimed |
| US-20160122403-A1 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION | MINTZ LIAT (US) | 2016-05-05 | — | — | US | claimed |
| WO-2015017123-A1 | GHRELIN SPLICE VARIANT FOR TREATING NEURONAL DAMAGE,NEURODEGENERATIVE DISEASE, PARKINSONS DISEASE, ALZHEIMERS DISEASE, AND/OR DEPRESSION | MINTZ LIAT (US) | 2015-02-05 | — | — | WO | claimed |
| CN-102596993-A | Multimeric peptide conjugates and uses thereof | ANGIOCHEM INC | 2012-07-18 | — | — | CN | claimed |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | claimed |
| US-7981860-B2 | Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation | MINTZ LIAT | 2011-07-19 | — | — | US | claimed |
| CN-101443358-A | Use of ghrelin splice variants for the treatment of cachexia and/or bulimia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation | LIAT MINTZ (US) | 2009-05-27 | — | — | CN | claimed |
| EP-2021365-A2 | USE OF GHRELIN SPLICE VARIANT FOR TREATING HIGH CHOLESTEROL LEVELS OR HIGH PLASMA GLUCOSE LEVELS AND RELEATED DISEASES | Mintz, Liat (US) | 2009-02-11 | — | — | EP | claimed |
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | CONJUCHEM, INC. (CA) | 2002-02-14 | — | — | US | claimed |
| US-20010018420-A1 | Method for alleviating pain or providing an analgesic effect in a patient | CONJUCHEM, LLC | 2001-08-30 | — | — | US | claimed |
| US-20010018421-A1 | Conjugate comprising an antinociceptive agent covalently bonded to a blood component | CONJUCHEM, LLC | 2001-08-30 | — | — | US | claimed |
| EP-1042003-A1 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | Conjuchem, Inc. (CA) | 2000-10-11 | — | — | EP | claimed |
| EP-1028971-A2 | NOVEL CONJUGATES OF RGD-CONTAINING PEPTIDES AND ENDOGENOUS CARRIERS | ConjuChem, Inc. (CA) | 2000-08-23 | — | — | EP | claimed |
| US-6107489-A | CHEMICALLY REACTIVE TRIPEPTIDE INTERMEDIATES WHICH CAN REACT WITH AVAILABLE REACTIVE FUNCTIONALITIES ON BLOOD COMPONENTS TO FORM COVALENT LINKAGES, THE RESULTING CONJUGATES HAVE RENIN INHIBITION ACTIVITY FOR EXTENDED PERIODS OF TIME | CONJUCHEM, INC. (CA) | 2000-08-22 | — | — | US | claimed |
| EP-1007561-A2 | NOVEL CONJUGATES OF OPIOIDS AND ENDOGENOUS CARRIERS | Conjuchem, Inc. (CA) | 2000-06-14 | — | — | EP | claimed |
| WO-1999048536-A2 | DELIVERY OF LONG LASTING THERAPEUTIC AGENTS BY FORMING COVALENT ATTACHMENTS IN VIVO | CONJUCHEM, INC. (CA) | 1999-09-30 | — | — | WO | claimed |
| WO-1999024074-A2 | NOVEL CONJUGATES OF OPIOIDS AND ENDOGENOUS CARRIERS | CONJUCHEM, INC. (CA) | 1999-05-20 | — | — | WO | claimed |
| WO-1999024462-A2 | NOVEL CONJUGATES OF RGD-CONTAINING PEPTIDES AND ENDOGENOUS CARRIERS | CONJUCHEM, INC. (CA) | 1999-05-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018420-A1 | Method for alleviating pain or providing an analgesic effect in a patient | OPRK1, OPRL1, OGFR | ALDH1A1 1843/4885DDB1 1496/4885CRBN 4161/4885 |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | LNPEP, DNPEP, VIP | ALDH1A1 4126/4885DDB1 2355/4885CRBN 1514/4885 |
| US-20020018751-A1 | CELLULAR AND SERUM PROTEIN ANCHORS FOR DIAGNOSTIC IMAGING | FABP3, VCAM1, TAGLN2 | ALDH1A1 4413/4885DDB1 509/4885CRBN 2586/4885 |
| US-20010018421-A1 | Conjugate comprising an antinociceptive agent covalently bonded to a blood component | OPRK1, OPRL1, OGFR | ALDH1A1 1754/4885DDB1 1466/4885CRBN 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.